We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $630M
1-Year Est. Return 108.65%
This Fund
S&P 500
This Quarter Est. Return
+12.99%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$725M
AUM Growth
+$66.7M
Cap. Flow
+$16.4M
Cap. Flow %
2.26%
Top 10 Hldgs %
41.88%
Holding
145
New
38
Increased
32
Reduced
27
Closed
36

Top Buys

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$25.1M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$19.4M
3
AMGN icon
Amgen
AMGN
+$17.7M
4
BLUE
bluebird bio
BLUE
+$12.8M
5
VTRS icon
Viatris
VTRS
+$11M

Top Sells

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$28.5M
2
REGN icon
Regeneron Pharmaceuticals
REGN
+$14.3M
3
SHPG
Shire pic
SHPG
+$11.3M
4
FOLD
Amicus Therapeutics
FOLD
+$9.93M
5
SRPT icon
Sarepta Therapeutics
SRPT
+$9.8M

Sector Composition

Rank Sector Weight
1 Healthcare 72.21%
2 Technology 6.12%
3 Financials 1.97%
4 Industrials 1.58%
5 Consumer Discretionary 1.41%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XNTK icon
1
PUT
State Street SPDR NYSE Technology ETF
XNTK
$2.06B
$71.4M 9.84%
+750,000
New +$69.1M
MRK icon
2
Merck
MRK
$322B
$41.3M 5.69%
712,640
+104,800
+17% +$5.91M
VTRS icon
3
Viatris
VTRS
$20.4B
$30.9M 4.26%
854,000
+280,000
+49% +$11M
GSK icon
4
GSK
GSK
$104B
$30.8M 4.25%
612,000
+212,000
+53% +$10.7M
GILD icon
5
Gilead Sciences
GILD
$162B
$25.1M 3.47%
+355,000
New +$25.1M
OEF icon
6
PUT
iShares S&P 100 ETF
OEF
$20.1B
$24.6M 3.39%
+150,000
New +$17.9M
SHPG
7
DELISTED
Shire pic
SHPG
$21.4M 2.94%
126,500
-70,000
-36% -$11.3M
ALXN
8
DELISTED
Alexion Pharmaceuticals
ALXN
$19.9M 2.75%
160,544
+78,544
+96% +$9.18M
ALNY icon
9
Alnylam Pharmaceuticals
ALNY
$27.5B
$19.2M 2.65%
+195,232
New +$19.4M
SRPT icon
10
Sarepta Therapeutics
SRPT
$1.57B
$19.2M 2.64%
145,096
-103,901
-42% -$9.8M
FOLD
11
DELISTED
Amicus Therapeutics
FOLD
$18.6M 2.56%
1,189,056
-656,648
-36% -$9.93M
AMGN icon
12
Amgen
AMGN
$208B
$18.5M 2.54%
+100,000
New +$17.7M
BIIB icon
13
Biogen
BIIB
$30B
$14.5M 2%
50,000
-15,000
-23% -$4.22M
PFE icon
14
Pfizer
PFE
$143B
$14.1M 1.95%
411,060
-210,800
-34% -$7.2M
CLSD
15
DELISTED
Clearside Biomedical
CLSD
$11.4M 1.58%
71,248
+2,581
+4% +$435K
BLUE
16
DELISTED
bluebird bio
BLUE
$11.4M 1.57%
+5,596
New +$12.8M
AGN
17
DELISTED
Allergan plc
AGN
$10M 1.38%
60,000
– –
CLLS
18
Cellectis
CLLS
$277M
$9.96M 1.37%
351,874
+12,507
+4% +$372K
TVTX icon
19
Travere Therapeutics
TVTX
$5.2B
$9.63M 1.33%
353,072
+133,072
+60% +$3.54M
ARQL
20
DELISTED
Arqule Inc
ARQL
$8.28M 1.14%
1,497,683
-766,453
-34% -$2.93M
NMTR
21
DELISTED
9 Meters Biopharma
NMTR
$7.84M 1.08%
49,025
– –
VKTX icon
22
Viking Therapeutics
VKTX
$3.7B
$7.42M 1.02%
782,424
-809,992
-51% -$5.39M
MSFT icon
23
Microsoft
MSFT
$3.45T
$7.34M 1.01%
74,435
+7,585
+11% +$735K
IMMU
24
DELISTED
Immunomedics Inc
IMMU
$7.26M 1%
306,655
-173,345
-36% -$3.48M
MLNX
25
DELISTED
Mellanox Technologies, Ltd.
MLNX
$7.25M 1%
85,954
-14,325
-14% -$1.17M
1
2 3 4 5

Similar funds

VIM
Vancity Investment Management Vancouver, British Columbia, Canada $629M AUM 2.49% 1-Year Est. Return
KCMH
Keywise Capital Management (HK) Hong Kong $630M AUM 81.01% 1-Year Est. Return
FCFC
First Commonwealth Financial Corp Indiana, Pennsylvania $629M AUM 20.47% 1-Year Est. Return
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return
PWW
Pettyjohn Wood & White Lynchburg, Virginia $628M AUM 20.96% 1-Year Est. Return
TTSTC
Texas Treasury Safekeeping Trust Company Austin, Texas $628M AUM 15.58% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Sphera Funds Management's Q2 2018 Portfolio in Review

As of Q2 2018, Sphera Funds Management held 145 positions worth $725M, up 10% from $659M the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Sphera Funds Management's Q2 2018 filing shows 38 new, 32 increased, 27 reduced and 36 closed positions. Its largest new stake was Gilead Sciences: 355,000 shares worth $25.1M. The largest sale was Celgene Corp, an estimated $28.5M.

By sector, the portfolio is most concentrated in Healthcare at 72% of assets, down from 75% a quarter earlier, followed by Technology and Financials.

  • Sphera Funds Management's largest Q2 2018 buy was Gilead Sciences: 355,000 shares worth $25.1M.
  • Sphera Funds Management added most to Viatris in Q2 2018, an estimated $11M increase.
  • Sphera Funds Management's biggest Q2 2018 reduction was Shire pic, cutting an estimated $11.3M.
  • Sphera Funds Management fully exited Celgene Corp in Q2 2018, selling an estimated $28.5M.
  • Sphera Funds Management's ten largest holdings make up 42% of its $725M portfolio in Q2 2018.
  • Sphera Funds Management opened 38 new positions and closed 36 in Q2 2018.
  • Sphera Funds Management's portfolio value rose 10% quarter-over-quarter to $725M.

Based on Sphera Funds Management's 13F filing for Q2 2018, filed 13 Aug 2018.